Company news
EchoIQ Limited news in 2024
EchoIQ Limited's news releases, calls and decks from 2024, newest first.
Pre-submission meeting with US FDA for heart failure
December 23, 2024
The First Step in EIQs US Market Commercialisation Strategy
December 8, 2024
S&P DJI Announces December 2024 Quarterly Rebalance
December 6, 2024
EIQ signs integration agreement with Flagship US Hospital
November 17, 2024
US Based CEO Appointed to Execute Commercialisation Strategy
October 8, 2024
Major Milestone Achieved with FDA Clearance for EchoSolv AS
October 7, 2024
Echo IQ Raises $7.1 million
September 6, 2024
Groundbreaking study results for Heart Failure AI solution
September 3, 2024
Strategic Integration Partnership Agreement with ScImage Inc
July 4, 2024
Validation of EIQ AI at Leading Scientific Conference
June 5, 2024
Investor Presentation
May 22, 2024
Echo IQ Commences New Heart Failure Clinical Study Using AI
May 20, 2024
US FDA Application Lodged
May 6, 2024
Quarterly Report
April 30, 2024
Appendix 4C Cash Flow Report
April 30, 2024
Management Update
April 1, 2024
Completion of US Reader Study
March 27, 2024
Receipt of Research & Development Tax Incentive
March 7, 2024
Appendix 4D 31 December 2023
February 28, 2024
RSH: Cardiovascular AI platform integrated into RPM program
January 24, 2024
EIQ Licenses Software to Respiri - Remote Patient Mon.
January 24, 2024
EIQ Appoints Kimber Rothwell as CEO
January 15, 2024
Decks in 2024
- Investor Presentation (May 2024)
Investor deck · 21 slides · May 23, 2024